Truvada 300mg. 200mg Tablet
PDF Leaflet Revision Date: 27 November 2015
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP) in HIV-negative adults.
Dosage (summary)
One tablet (200 mg emtricitabine and 300 mg tenofovir) once daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; avoid breastfeeding to prevent HIV transmission.
Key Drug Interactions
- Avoid co-administration with other tenofovir or emtricitabine products
- Monitor for nephrotoxic agents
Contraindications
- Hypersensitivity to components
- Creatinine clearance < 60 ml/min for PrEP
- Creatinine clearance < 50 ml/min for HIV treatment
Common side effects
- Dizziness
- Diarrhea
- Nausea
- Fatigue
- Rash
Counselling Points
- Adhere strictly to dosing schedule
- Use additional preventive measures for HIV transmission
- Monitor for signs of lactic acidosis
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Risk of hepatitis B exacerbation upon discontinuation
Important Disclaimer
The Truvada 300mg. 200mg Tablet professional information leaflet below is the property of Aspen Pharmacare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
